Neurological Sciences

, Volume 31, Supplement 3, pp 309–312

The cohort of the multiple sclerosis center of Cagliari

  • M. G. Marrosu
  • L. Lorefice
  • J. Frau
  • G. Coghe
  • G. Fenu
  • R. Piras
  • M. Melis
  • E. Cocco
Session II – Natalizumab: Italian Experience

DOI: 10.1007/s10072-010-0470-7

Cite this article as:
Marrosu, M.G., Lorefice, L., Frau, J. et al. Neurol Sci (2011) 31: 309. doi:10.1007/s10072-010-0470-7

Abstract

We report our experience in long-term treatment of relapsing remitting multiple sclerosis patients with natalizumab (N). In November 2009 we evaluated 141 patients (126 AIFA criterion A, 15 AIFA criterion B). We paid particular attention to the treatment period and the patients follow-up; during the whole therapeutic program, they undergone to clinical and radiological evaluation for every 3 months. The compliance was optimal and we found no significant side effects. 26 patients completed the 24 monthly doses. After 24 months 51% of patients were free from disease activity. We found a reduction in relapses and EDSS, moreover the clinical improvement was also confirmed by radiological examinations. Our results show that the best therapeutic results are achieved by early initiation of treatment.

Keywords

Multiple sclerosisNatalizumabPatient management

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • M. G. Marrosu
    • 1
  • L. Lorefice
    • 1
  • J. Frau
    • 1
  • G. Coghe
    • 1
  • G. Fenu
    • 1
  • R. Piras
    • 1
  • M. Melis
    • 1
  • E. Cocco
    • 1
  1. 1.Centro Sclerosi Multipla, Dipartimento di Scienze Cardiovascolari e NeurologicheUniversità di CagliariCagliariItaly